Procter & Gamble (PG) Q2 Earnings Preview: $22.29B Revenue, $1.86 EPS Expected
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: seekingalpha
- Earnings Forecast: Procter & Gamble anticipates Q2 EPS of $1.86, reflecting a 1.1% year-over-year decline, with projected revenue of approximately $22.29 billion, indicating a modest 1.8% growth, showcasing resilience amid economic pressures.
- Sales Pressure: The company faces sales challenges in the U.S. due to the temporary suspension of federal food assistance and broader economic headwinds, with management warning that a government shutdown could exacerbate domestic volume softness.
- Analyst Ratings: Jefferies has named PG among its favorite household product stocks, citing restructuring tailwinds and innovation-led growth, while Seeking Alpha rates it as Hold, indicating market concerns over its valuation.
- Performance Record: Over the past two years, PG has beaten EPS estimates 100% of the time and revenue estimates 38% of the time, yet recent months have shown no upward revisions in EPS and revenue estimates, reflecting cautious market sentiment regarding future growth.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like PG with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on PG
Wall Street analysts forecast PG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PG is 164.50 USD with a low forecast of 150.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
10 Buy
7 Hold
0 Sell
Moderate Buy
Current: 147.340
Low
150.00
Averages
164.50
High
180.00
Current: 147.340
Low
150.00
Averages
164.50
High
180.00
About PG
The Procter & Gamble Company is focused on providing branded consumer packaged goods to consumers across the world. The Company’s segments include Beauty, Grooming, Health Care, Fabric & Home Care and Baby, Feminine & Family Care. The Company’s products are sold in approximately 180 countries and territories primarily through mass merchandisers, e-commerce, including social commerce channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores, including airport duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. It also sells direct to individual consumers. It has operations in approximately 70 countries. It offers products under brands, such as Head & Shoulders, Herbal Essences, Pantene, Rejoice, Olay, Old Spice, Safeguard, Secret, SK-II, Braun, Gillette, Venus, Crest, Oral-B, Ariel, Downy, Gain, Tide, Always, Always Discreet, Tampax, Bounty and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of High-Yield Stock Investment Opportunities
- Stable Income from Realty Income: Realty Income boasts a dividend yield of 5.3% and has increased its monthly dividend for 30 consecutive years, reflecting its solid investment-grade balance sheet and conservative management approach, making it a cornerstone investment for conservative investors.
- Procter & Gamble's Dividend King Status: As one of the largest consumer goods companies globally, Procter & Gamble faces volume declines due to economic slowdowns, yet its 2.8% dividend yield and over 60 years of annual dividend increases make it attractive in uncertain markets.
- Pfizer's Turnaround Challenges: Pfizer offers a high dividend yield of 6.7%, but investor sentiment is low due to patent expirations and challenges in drug development; however, the company is actively acquiring promising drug pipelines to navigate current setbacks.
- Diverse Investment Options: Realty Income, Procter & Gamble, and Pfizer each present unique characteristics and yields above market averages, requiring investors to align their investment goals with these opportunities.
Continue Reading
Apple Stock Down 8.8%: Analyzing the Causes
- Poor Stock Performance: Apple has seen an 8.8% decline year-to-date, making it the second-worst performer in the Dow Jones Industrial Average, contrasting sharply with the S&P 500's 1% gain, indicating market concerns over its growth prospects.
- AI Integration Progress: Apple's joint announcement with Google to integrate Gemini models and cloud technology into its next-generation foundation models, with a Gemini-powered Siri expected in February, highlights its strategic push into AI, potentially enhancing user experience and competitive positioning.
- Improving Financials: In fiscal 2025, Apple's product revenue grew by 4.1% and services revenue surged by 13.5%, with product gross margins at 36.8% and services at an impressive 75.4%, indicating a recovery in profitability and demand.
- High Valuation: Despite improving earnings and margins, Apple's forward P/E ratio of 30.9 remains higher than competitors like Amazon and Alphabet, prompting investors to carefully assess its relative value amid uncertainties in consumer spending.
Continue Reading